Preclinical model for evaluating human TCRs against chimeric syngeneic tumors.

ABSTRACT:

Background

The adoptive cell transfer (ACT) of T cell receptor (TCR)-engineered T cells targeting the HLA-A2-restricted epitope NY-ESO-1_157-165 (A2/NY) has yielded important clinical responses against several cancers. A variety of approaches are being taken to augment tumor control by ACT including TCR affinity-optimization and T-cell coengineering strategies to address the suppressive tumor microenvironment (TME). Most TCRs of clinical interest are evaluated in immunocompromised mice to enable human T-cell engraftment and do not recapitulate the dynamic interplay that occurs with endogenous immunity in a treated patient. A variety of humanized mouse models have been described but they have limitations in immune reconstitution and are technically challenging to implement

SUBMITTER: Semilietof A 

PROVIDER: S-EPMC11667476 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature